Memantine Eg (Memantine Hydrochloride)

Memantine acts as an uncompetitive antagonist of the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor‑associated ion channel at a site distinct from the glutamate binding site, it blocks excessive calcium influx that occurs during pathological activation, thereby reducing excitotoxic neuronal injury that contributes to cognitive decline in Alzheimer’s disease.

The specific dose of Memantine Eg is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and tolerability. Typical titration starts with a low dose that is gradually increased to the target maintenance dose, but exact dosing regimens should only be provided by a qualified healthcare professional.

The safety of memantine in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and use is generally reserved for situations where the potential benefit to the mother outweighs any possible risk to the fetus. Breastfeeding mothers should consult their physician before using the medication.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Memantine Eg. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas other approved agents such as donepezil, rivastigmine, and galantamine are acetylcholinesterase inhibitors. Memantine is typically used in moderate to severe stages, often in combination with an acetylcholinesterase inhibitor, and its mechanism focuses on reducing excitotoxicity rather than enhancing cholinergic transmission.

Store Memantine Eg at ambient temperature, below 25 °C (77 °F). Keep the tablets in the original packaging to protect them from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Memantine Eg is taken orally, usually as a tablet, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and should not split, crush, or chew the tablet unless specifically instructed.

Although uncommon, serious adverse reactions can include severe skin reactions such as Stevens‑Johnson syndrome, seizures, significant hypertension, and hepatic dysfunction. Patients should seek immediate medical attention if they experience rash, blistering, unexplained seizures, or signs of liver injury such as jaundice or dark urine.

Memantine Eg should be avoided in patients with known hypersensitivity to memantine or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled hypertension, or a history of seizures. It is also contraindicated in patients receiving other NMDA antagonists without medical supervision.